Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies


Developing and maintaining robust enzyme assays is a key component of many drug discovery programs. Our scientists are well versed in enzymology being experts at optimising activity, characterising enzyme kinetics and determining mechanisms of inhibition, enabling the delivery of high quality data to inform your discovery program.

At Sygnature Discovery, we have substantial experience in the development of tailored screening assays across a plethora of enzyme classes (e.g. kinases, phosphatases, proteases, oxidoreductases, ATPases, transferases, lyases). Sygnature’s scientists utilise a range of technology platforms to allow the development of sensitive, tailored assays across a diverse range of enzyme classes. These assays can be used to measure change in [substrates] and [products] directly or indirectly and include:

Figure 1: The mechanism of action of an enzyme inhibitor can be determined from its effect on Michaelis-Menten kinetics. Here a non-competitive inhibitor lowers the Vmax but does not affect the KM value.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.